SCHEMBL22290255

SCHEMBL22290255

CC1(C)OB(c2cccc(C(=O)Nc3ccncc3)c2)OC1(C)C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NT5E P21589 1/20 0.58
JAK2 O60674 1/20 0.51
TYK2 P29597 1/20 0.51
ROCK2 O75116 2/20 0.51
ROCK1 Q13464 2/20 0.51
HTT P42858 2/20 0.51
LMNA P02545 1/20 0.51
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
SIRT2 Q8IXJ6 1/20 0.48
KCNK3 O14649 2/20 0.48
KCNK9 Q9NPC2 1/20 0.48
KDM4E B2RXH2 2/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
ALDH1A1 P00352 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14568092 0.88 HDAC1 (0.52) LMNACA1CA2CA9KCNK3
SCHEMBL18343191 0.88 KCNK3 (0.57) NT5EJAK2TYK2HTTLMNA
SCHEMBL31224954 0.86 TP53 (0.57) CA1CA2CA9NPC1RAB9A
SCHEMBL14120424 0.85 KMT2A (0.61) CA1CA2CA9L3MBTL1KMT2A
SCHEMBL14120398 0.84 CA1 (0.56) CA1CA2CA9NPC1RAB9A
SCHEMBL18343409 0.83 KCNK3 (0.61) ROCK2ROCK1HTTLMNAKCNK3
SCHEMBL20995745 0.83 NPC1 (0.62) LMNACA1CA2CA9KDM4E
SCHEMBL15650180 0.82 MEN1 (0.61) HTTLMNACA1CA2CA9
SCHEMBL31224822 0.81 P4HB (0.54) CA1CA2CA9NPC1RAB9A
SCHEMBL31224827 0.81 PIM1 (0.54) ROCK2CA1CA2CA9NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 EP disclosed
US-20230079819-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-16 US disclosed
EP-3917527-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 EP disclosed
CN-113645971-A Compound and use thereof 福宏治疗公司 2021-11-12 CN disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079819-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB NT5E 4342/4885JAK2 2417/4885TYK2 2511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.